Incyte Corporation
General ticker "INCY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $14.3B (TTM average)
Incyte Corporation follows the US Stock Market performance with the rate: 58.9%.
Estimated limits based on current volatility of 1.6%: low 100.68$, high 104.03$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 2617 (+3.7%) as of 2024
- US accounted for 94.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Labor/talent shortage/retention, Strategic risks and growth management, Market disruptions, Operational and conduct risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [67.20$, 107.28$]
- 2025-12-31 to 2026-12-31 estimated range: [74.15$, 116.71$]
Financial Metrics affecting the INCY estimates:
- Negative: with PPE of 52.1 at the end of fiscal year the price was very high
- Positive: -3.60 < Operating profit margin, % of 1.45
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 63.33 <= 63.39
- Positive: Inventory ratio change, % of -0.31 <= 0
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: 0.01 < Interest expense per share per price, % of 0.02
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of 0.60
Short-term INCY quotes
Long-term INCY plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3,394.64MM | $3,695.65MM | $4,241.22MM |
| Operating Expenses | $2,815.20MM | $3,075.12MM | $4,179.85MM |
| Operating Income | $579.44MM | $620.52MM | $61.37MM |
| Non-Operating Income | $-50.32MM | $213.69MM | $255.26MM |
| Interest Expense | $2.67MM | $2.55MM | $2.28MM |
| R&D Expense | $1,585.94MM | $1,627.59MM | $2,606.85MM |
| Income(Loss) | $529.12MM | $834.22MM | $316.63MM |
| Taxes | $188.46MM | $236.62MM | $284.01MM |
| Profit(Loss)* | $340.66MM | $597.60MM | $32.62MM |
| Stockholders Equity | $4,370.12MM | $5,189.84MM | $3,447.63MM |
| Inventory | $41.99MM | $62.97MM | $58.87MM |
| Assets | $5,840.98MM | $6,782.11MM | $5,444.32MM |
| Operating Cash Flow | $969.94MM | $496.49MM | $335.34MM |
| Capital expenditure | $77.83MM | $47.49MM | $86.26MM |
| Investing Cash Flow | $-78.54MM | $-207.68MM | $157.52MM |
| Financing Cash Flow | $-0.79MM | $-20.03MM | $-2,021.55MM |
| Earnings Per Share** | $1.53 | $2.67 | $0.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.